Tesla stock (NASDAQ: TSLA) tumbled over 3.5% in the early trading on Monday as the electric carmaker confronts a convergence of structural headwinds. ...

Core Insights - Meta Platforms is making significant investments in AI, which are expected to lead to higher Return on Invested Capital (ROIC) and should not raise concerns regarding the company's substantial capital expenditures [1]. Group 1: Company Overview - Meta Platforms is focused on leveraging AI technology to enhance its financial performance and operational efficiency [1]. Group 2: Investment Perspective - The company's high capital expenditures are viewed positively in the context of long-term value creation and potential returns from AI investments [1].

Warner Bros Discovery is likely to hold a shareholder vote on the $82.7 billion deal to sell its streaming and studio assets to Netflix in March, CNBC reported on Monday. ...

Core Insights - SEQSTER and Praxis Precision Medicines have expanded their partnership to enhance clinical trials, data collection, and real-world evidence generation for Praxis's clinical development programs [1][2][4] Group 1: Partnership and Collaboration - SEQSTER has been integral to Praxis's clinical trial execution, improving trial enrollment efficiency and capturing necessary longitudinal real-world data [2][3] - The partnership focuses on advancing the ENERGY program, which includes the EMPOWER observational study and POWER clinical studies, attracting over 5,000 patients with epilepsy [3][4] Group 2: Company Profiles - Praxis Precision Medicines is a leading biopharmaceutical company specializing in central nervous system (CNS) disorders, utilizing genetic insights to develop therapies for various neurological conditions [5] - SEQSTER is a healthcare technology company that consolidates patient-consented health data into a unified view, supporting research and patient health management with a repository of 150 million patients [6][7]

You know that expectations for a company are sky high when it can report a 60% year-over-year jump in profits, a 17% rise in revenue, a 45% increase in users of its flagship product, and $12.7 billion returned to shareholders that quarter ... and the stock still tanks by 10% the next day. Microsoft (NASDAQ: MSFT) was the victim of this expectations hit last Thursday, as Wall Street digested its Q2 2026 earnings report released the day before. The sell-off wiped away a staggering $357 billion from the tech ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks. TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several models and price estimates throughout its biotechnology coverage, as well as an update to its 2026 Catalyst Tracker. Separately, on December 3, 2025, Black Dia ...

A lot of people end up relying heavily on Social Security for income once they retire. And if you're in the same boat, you might appreciate a boost to your monthly checks. Of course, one nice thing about Social Security is that benefits are eligible for a cost-of-living adjustment (COLA) each year. But those boosts don't tend to go very far, especially since they typically end up trailing inflation instead of keeping up with it. Where to invest $1,000 right now? Our analyst team just revealed what they be ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the best biotech stocks on our list is Altimmune, Inc. TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target. Strong underlying fundamentals, continuous merger and acquisition activity, and alleviating medication pricing concerns are the reasons behind the firm’s optimistic outlook for the biotech industry in 2026. Additionally, Barclays pointed out that A ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" to maximize returns in a shorter time frame [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lose momentum if future growth does not justify high valuations [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify promising candidates [3] Group 2: SSAAY Stock Analysis - SSAAY has shown a four-week price change of 8.3%, indicating growing investor interest and positioning it well within the momentum investing framework [4] - Over the past 12 weeks, SSAAY has gained 30.8%, with a beta of 1.35, suggesting it moves 35% more than the market in either direction [5] - SSAAY has a Momentum Score of B, indicating a favorable time to invest based on its momentum characteristics [6] Group 3: Earnings Estimates and Valuation - SSAAY has received upward revisions in earnings estimates, earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects as analysts raise their estimates [7] - The stock is currently trading at a Price-to-Sales ratio of 0.86, suggesting it is undervalued, as investors pay only 86 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides SSAAY, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing - Momentum investors often face challenges in determining the right entry point, as stocks may lose momentum when their valuations exceed future growth potential [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Algoma Steel Group Inc. (ASTL) - Algoma Steel Group Inc. (ASTL) has shown a price increase of 6.6% over the past four weeks, indicating growing investor interest [4] - The stock has gained 8.3% over the past 12 weeks, with a beta of 1.56, suggesting it moves 56% higher than the market [5] - ASTL has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investors [7] - ASTL is trading at a Price-to-Sales ratio of 0.28, meaning investors pay only 28 cents for each dollar of sales, indicating a reasonable valuation [7] Group 3: Additional Investment Opportunities - Besides ASTL, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies tailored to help investors find winning stock picks [9]